Peran Asam Lemak Omega-3 (EPA versus DHA) dalam Tata Laksana Gangguan Mood: Sebuah Tinjauan Naratif
DOI:
https://doi.org/10.31004/ijisk.v3i3.450Keywords:
asam lemak omega-3; EPA; DHA; gangguan depresi mayor; gangguan bipolarAbstract
Latar belakang: Gangguan mood, terutama gangguan depresi mayor (major depressive disorder/MDD) dan gangguan bipolar, merupakan penyumbang utama beban disabilitas global, sementara farmakoterapi konvensional masih dibatasi oleh respons parsial, awitan lambat, dan efek samping. Asam lemak tidak jenuh ganda rantai panjang omega-3 (n-3 PUFA), khususnya asam eikosapentaenoat (EPA) dan asam dokosaheksaenoat (DHA), telah lama diteliti sebagai terapi tambahan, namun peran diferensial keduanya masih diperdebatkan. Tujuan: Merangkum dan menyintesis bukti mekanistik dan klinis terkini mengenai peran EPA versus DHA pada gangguan mood serta implikasinya terhadap praktik. Metode: Tinjauan naratif terhadap meta-analisis, uji acak terkontrol (randomized controlled trial/RCT), dan pedoman praktik yang ditelusuri dari PubMed, Scopus, dan Google Scholar. Pembahasan: Bukti secara konsisten menunjukkan bahwa formulasi dengan proporsi EPA tinggi (≥60% dari total EPA+DHA) pada dosis ≤1–2 g/hari memberikan efek antidepresan, sedangkan formulasi dominan-DHA tidak. Mekanisme yang diusulkan mencakup resolusi inflamasi melalui mediator lipid pro-resolving, jalur sitokrom P-450 dan endokanabinoid yang khas EPA, serta modulasi membran, neurotransmisi, dan neuroplastisitas yang lebih terkait DHA. Pada gangguan bipolar, n-3 memperbaiki gejala depresi tetapi tidak gejala mania. Pedoman International Society for Nutritional Psychiatry Research (ISNPR) merekomendasikan 1–2 g EPA netto/hari sebagai terapi adjuvan. Kesimpulan: EPA tampaknya merupakan komponen utama yang bertanggung jawab atas efek antidepresan omega-3, dengan DHA berperan lebih struktural; penggunaannya bersifat tambahan, bukan pengganti terapi standar.
References
GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137–50.
Guu TW, Mischoulon D, Sarris J, Hibbeln J, McNamara RK, Hamazaki K, dkk. International Society for Nutritional Psychiatry Research practice guidelines for omega-3 fatty acids in the treatment of major depressive disorder. Psychother Psychosom. 2019;88(5):263–73.
Kalkman HO, Hersberger M, Walitza S, Berger GE. Disentangling the molecular mechanisms of the antidepressant activity of omega-3 polyunsaturated fatty acid: a comprehensive review of the literature. Int J Mol Sci. 2021;22(9):4393.
Bozzatello P, Brignolo E, De Grandi E, Bellino S. Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data. J Clin Med. 2016;5(8):67.
Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr. 2009;28(5):525–42.
Hallahan B, Ryan T, Hibbeln JR, Murray IT, Glynn S, Ramsden CE, dkk. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br J Psychiatry. 2016;209(3):192–201.
Sublette ME, Ellis SP, Geant AL, Mann JJ. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry. 2011;72(12):1577–84.
Grosso G, Pajak A, Marventano S, Castellano S, Galvano F, Bucolo C, dkk. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One. 2014;9(5):e96905.
Mocking RJT, Harmsen I, Assies J, Koeter MWJ, Ruhé HG, Schene AH. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry. 2016;6(3):e756.
Liao Y, Xie B, Zhang H, He Q, Guo L, Subramaniapillai M, dkk. Efficacy of omega-3 PUFAs in depression: a meta-analysis. Transl Psychiatry. 2019;9(1):190.
Mozaffari-Khosravi H, Yassini-Ardakani M, Karamati M, Shariati-Bafghi SE. Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: a randomized, double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2013;23(7):636–44.
Mischoulon D, Nierenberg AA, Schettler PJ, Kinkead BL, Fehling K, Martinson MA, dkk. A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. J Clin Psychiatry. 2015;76(1):54–61.
Appleton KM, Voyias PD, Sallis HM, Dawson S, Ness AR, Churchill R, dkk. Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev. 2021;11(11):CD004692.
Okereke OI, Vyas CM, Mischoulon D, Chang G, Cook NR, Weinberg A, dkk. Effect of long-term supplementation with marine omega-3 fatty acids vs placebo on risk of depression or clinically relevant depressive symptoms and on change in mood scores: a randomized clinical trial. JAMA. 2021;326(23):2385–94.
Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012;73(1):81–6.












